This superiority in PFS in the current study might infer that Korean patients with ALK‐positive NSCLC may receive a longer effect of crizotinib than Western patients, due to different resistance‐acquiring mechanisms or other traits of ALK‐positive NSCLC, although they show a relatively low response rate to crizotinib. The gene discussed is ALK; the disease is non-small cell lung carcinoma.